Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 12,
Issue 1
January 2023

Biology Open (BiO) is an Open Access journal that publishes rigorously conducted high-quality research across the breadth of the biological and biomedical sciences. It provides timely, thorough, constructive and fair peer review, with a focus on supporting researchers and reducing the pain to publish.

Our international board of research-active academic Editors, led by Editor-in-Chief Steven Kelly, comprises leaders in their respective fields. The BiO team is committed to Open Access publishing as a mechanism to widen access, promote equality and ensure sustainability in publishing in the biological and biomedical sciences.

Twitter-icon  Facebook-icon  YouTube-icon  RSS-icon

BiO included in Read & Publish agreements

From 2022, BiO is included in many of the Read & Publish agreements offered by The Company of Biologists. This enables discounted or fee-free publication of an uncapped number of Research articles in BiO for corresponding authors at participating institutions (including, among others, the Max Planck Digital Library and University of California).

BiO fast-track option

Do you have a paper with reviews from another journal?

BiO editors will fast track your paper and give you an initial decision within one week. 

Send us your manuscript together with the full set of reviews and decision letters, and we will make an initial decision in one week (or less).

There is no need to reformat your manuscript.

Find out more here. Submit to BiO here.

Future Leader Reviews

Actin cytoskeleton in angiogenesis by Nidhi Yadunandanan Nair, Victor Samuel, Lariza Ramesh, Areeba Marib, Deena T. David and Ananthalakshmy Sundararaman

Sundararaman and colleagues synthesize our current understanding of the roles of actin in vascular morphogenesis, describing how endothelial actin structures and actin-mediated force generation coordinate the multi-step angiogenic process.

The prospect of genetically engineering natural killer cells for cancer immunotherapy by Angie Yu Ching Poon and Ryohichi Sugimura

The authors review recent progress in the use of natural killer (NK) cells for cancer immunotherapy, from the basics of NK cell biology to chimeric antigen receptor-transduced NK cell applications.

Recently published in BiO

What drives mixed-species shoaling among wild zebrafish? The roles of predators, food access, abundance of conspecifics and familiarity by Ishani Mukherjee and Anuradha Bhat

In their natural habitats, zebrafish often shoal with co-occurring species. This study reveals that food apportionment, benefits related to predator avoidance, and familiarity are potential drivers of mixed-species shoaling among zebrafish.

Requirement for STAT3 and its target, TFCP2L1, in self-renewal of naïve pluripotent stem cells in vivo and in vitro by Sophie Kraunsoe, Takuya Azami, Yihan Pei, Graziano Martello, Kenneth Jones, Thorsten Boroviak and Jennifer Nichols

Inducing diapause in mouse embryos demonstrates that STAT3 and TFCP2L1 are essential for self-renewal of the epiblast, but only TFCP2L1 is required for derivation of embryonic stem cells.

Supporting BiO's community

Euglena International Network (EIN): Driving euglenoid biotechnology for the benefit of a challenged world

Members of the Euglena International Network describe how euglenoids show great promise to benefit our world, as biofuels, robotics design simulators, cancer treatments and food nutritional agents, but the absence of reference genomes currently limits the realization of these benefits.

Journals from The Company of Biologists

Development current cover
Journal of Cell Science current cover
Journal of Experimental Biology current cover
Disease Models and Mechanisms current cover
Biology Open current cover
Close Modal

or Create an Account

Close Modal
Close Modal